Immunohistochemistry of pulmonary biomarkers: A perspective from members of the Pulmonary Pathology Society Journal Article


Authors: Thunnissen, E.; Allen, T. C.; Adam, J.; Aisner, D. L.; Beasley, M. B.; Borczuk, A. C.; Cagle, P. T.; Capelozzi, V. L.; Cooper, W.; Hariri, L. P.; Kern, I.; Lantuejoul, S.; Miller, R.; Mino-Kenudson, M.; Radonic, T.; Raparia, K.; Rekhtman, N.; Roy-Chowdhuri, S.; Russell, P.; Schneider, F.; Sholl, L. M.; Tsao, M. S.; Vivero, M.; Yatabe, Y.
Article Title: Immunohistochemistry of pulmonary biomarkers: A perspective from members of the Pulmonary Pathology Society
Abstract: The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes. © Copyright 2018 College of American Pathologists.
Journal Title: Archives of Pathology & Laboratory Medicine
Volume: 142
Issue: 3
ISSN: 0003-9985
Publisher: College of American Pathologists  
Date Published: 2018-03-01
Start Page: 408
End Page: 419
Language: English
DOI: 10.5858/arpa.2017-0106-SA
PROVIDER: scopus
PUBMED: 28686497
DOI/URL:
Notes: Review -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Natasha Rekhtman
    209 Rekhtman